73
Views
16
CrossRef citations to date
0
Altmetric
Original Articles

Prospective, Open-Label Comparative Study of Liver Toxicity in an Unselected Population of HIV-Infected Patients Treated for the First Time with Efavirenz or Nevirapine

, &
Pages 302-311 | Published online: 02 Feb 2015

REFERENCES

  • Rancinan C, Neau D, Saves M, et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS. 2002;16:1357–1362.
  • Perez-Molina JA. Safety and tolerance of efavirenz in dif-ferent antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected pa-tients. HIV Clin Trials. 2003;3:279–286.
  • Milinkovic A, Martinez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther. 2004;2:367–373.
  • Manfredi R. HIV infection, antiretroviral therapy, and he-patic function. Emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management. AIDS. 2003;17:2253–2256.
  • Verucchi G, Calza L, Manfredi R, Chiodo F. Incidence of liver toxicity in HIV-infected patients receiving isolated dual nucleoside analogue antiretroviral therapy. J Acquir Im-mune Defic Syndr. 2003;33:546–548.
  • Chiesa E, Bini T, Adorni F, et al. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Antivir Ther. 2003;8:27–35.
  • Sulkowski MS, Thomas DL, Metha SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182–189.
  • Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine- and efavirenz-containing regi-mens in HIV-infected patients. Int J STD AIDS. 2003;14:776–781.
  • Kontorinis N, Dieterich DT. Toxicity of non-nucleoside ana-logue reverse transcriptase inhibitors. Semin Liver Dis. 2003;23:172–182.
  • Bell C, Matthews GV, Nelson MR. Non-nucleoside reverse transcriptase inhibitors - a overview. Int J STD AIDS. 2003;14:71–77.
  • Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34\(suppl 1):521–533.
  • Martin-Carbonero L, Nuriez M, Gonzalez-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003;4:115–120.
  • Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 200115: 1261–1268.
  • Gonzalez de Requeria D, Nuriez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS. 2002;16:290-291.
  • Wit RN, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence and risk factors for severe hepatotoxicity associ-ated with antiretroviral combination therapy. J Infect Dis. 2002;186:23–31.
  • Van Heeswijk RP, Veldkamp Al, Mulder IW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000;14:F77–F82.
  • Van Leth F, Phanuphak P, Ruxtungtham K, et al. Compari-son of first-line antiretroviral therapy with regimens includ-ing nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised, open-label trial, the 2 NN study. Lancet. 2004;63:1253–1263.
  • Palmon R, Koo BC, Shoulz DA, Dieterich DT. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 200229: 340–345.
  • Soriano V, Martin-Carbonero L, Garcia-SamaniegoJ, Puoti M. Mortality due to chronic viral liver disease among pa-tients infected with human immunodeficiency virus. Clin Infect Dis. 2001;33:1793–1795.
  • Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis. 2002;186:1023–1027.
  • Manfredi R, Calza L, Chiodo F. Gabexate mesilate and/or octreotide in human immunodeficiency virus-associated pancreatic abnormalities. Aliment Pharmacol Ther. 2002;16:1791–1794.
  • Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA. JAMA. 2004;292:251–265.
  • Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label ob-servational study. J Acquir Immune Defic Syndr. 2004;35:492–502.
  • Manfredi R, Calza L, Chiodo F. A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use. J Antimicrob Chemother. 2002;49:723–729.
  • Manfredi R, Calza L, Chiodo F. First line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. AIDS. 2004;28:2331–2333.
  • Dieterich DT, Robinson PA, Love J, Stern JO. Drug-in-duced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38\(suppl 2):580–S89.
  • Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, Bennett C. Serious adverse cutaneous and hepatic toxici-ties associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2004;35:120–125.
  • De Maat MM, Mathot RA, Veldkamp Al, et al. Hepatotoxic-ity following nevirapine-containing regimens in HIV-1 in-fected individuals. Pharmacol Res. 2002;46:295–300.
  • Nuriez M, Gonzalez-Requena D, Gonzalez-Lahoz J, Soriano V. Interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. AIDS Res Hum Retroviruses. 2003;19:187–188.
  • Dailly E, Billaud E, Reliquet V, et al. No relationship be-tween high nevirapine plasma concentration and hepato-toxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin PharmacoL 2004;60:343–348.
  • Almond LM, Boffito M, Hoggard PG, et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses. 2004;20:716–722.
  • De Maat MM, Huitema AD, Mulder JW, Meenhorst PL, Van Gorp EC, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected indi-viduals. Br J Clin Pharmacol. 2002;53:552P.
  • Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother. 2002;36:1598–1613.
  • Verucchi G, Calza L, Manfredi R, Chiodo F. Human immu-nodeficiency virus and hepatitis C virus coinfection: epide-miology, natural history, therapeutic options and clinical management. Infection. 2004;32:33–46.
  • Diaz B, Martin-Carbonero L, Perez-Olmeda M, Soriano V. Normalization of liver enzymes in an HIV-hepatitis C virus co-infected patients after potent antiretroviral therapy. AIDS. 2002;16:1193.
  • Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidemic therapy with bezafibrate. J Infect. 200142: 181–188.
  • Manfredi R, Calza L, Chiodo F. Gynecomastia, lipodystro-phy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones. J Acquir Immune Defic Syndr. 2003;35:99–102.
  • Manfredi R, Calza L, Chiodo F. A case-control study of HIV-associated pancreatic abnormalities during HAART era. Focus on emerging risk factors and specific manage-ment. Eur J Med Res. 2004;9:537–544.
  • Manfredi R, Calza L, Chiodo F. An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J Acquir Immune Defic Syndr. 2005;38:236–238.
  • Manfredi R. HIV disease and advanced age. An increasing therapeutic challenge. Drugs Aging. 2002;19:647–669.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.